Horizon Therapeutics, Inc., a privately held biopharmaceutical enterprise, announced that it be closing enrollment within its two stair 3 trial HZ-CA-301 and HZ-CA-303 in favour of its make plans for goods claimant HZT-501, an investigational prescription NSAID (non-steroidal anti-inflammatory drug) designed to be “GI-friendly”.
“We enrol completed fifteen hundred patients in smaller [...]
